The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients
| Autor: | Goran Trajkovic, Jelena Jelicic, Jelena Bila, Aleksandra Sretenovic, Darko Antic, Biljana Mihaljevic, Marija Dencic Fekete, Maja Perunicic Jovanovic |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Anemia health care facilities manpower and services Eligibility Determination Kaplan-Meier Estimate Risk Assessment 03 medical and health sciences 0302 clinical medicine Risk groups Autologous stem-cell transplantation Germany health services administration Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Staging system Multiple myeloma Aged Neoplasm Staging Aged 80 and over Univariate analysis business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Prognosis medicine.disease Transplant Recipients Thalidomide Clinical trial Treatment Outcome 030220 oncology & carcinogenesis Female Multiple Myeloma business human activities 030215 immunology medicine.drug |
| Zdroj: | Oncology Research and Treatment. 40:616-620 |
| ISSN: | 2296-5262 2296-5270 |
| DOI: | 10.1159/000478935 |
| Popis: | Background: The Revised International Staging System (R-ISS) has recently been introduced as a comprehensive prognostic score for multiple myeloma (MM). Validation of the R-ISS in patients treated outside of clinical trials is the focus of current investigations. The aim of this study was to test the prognostic role of the R-ISS in MM patients ineligible for autologous stem cell transplantation. Patients and Methods: A total of 102 newly diagnosed MM patients were analyzed. All patients were initially treated with thalidomide-based combinations. Results: An overall response rate was achieved in 77.4% patients. Both the International Staging System (ISS) and the R-ISS influenced the event-free survival and the overall survival (OS). However, the ISS was unable to discriminate patients in stages ISS1 and ISS2 regarding OS. On the contrary, the R-ISS clearly differentiated risk categories regarding OS and provided an improved discriminative power of 6.3% compared to the ISS. Furthermore, among the parameters that were significant in univariate analysis (presence of renal impairment, anemia, platelet count < 130 × 109/l, and R-ISS), the multivariate model pointed to the R-ISS (p = 0.001) as the most important parameter influencing OS. Conclusion: The R-ISS represents a useful tool for risk stratification of transplant-ineligible MM patients and should be considered as a prognostic index in daily clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|